References

Cancer treatment and survivorship statistics, 2025

2025 · External reference

A bayesian network meta-analysis of systemic treatments for metastatic castration-resistant prostate cancer in First- and subsequent lines

10.1007/s11523-025-01148-2 · 2025 · External reference

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

10.1016/s1470-2045(14)71205-7 · 2015 · External reference

Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study

10.1016/j.eururo.2016.07.032 · 2017 · External reference

Cabazitaxel versus abiraterone or enzalutamide for poor-prognosis metastatic castration-resistant prostate cancer after docetaxel: a phase 2 trial with a circulating tumor DNA analysis

2025 · External reference

External validation of a prognostic model of overall survival in men with chemotherapy-naive metastatic castration-resistant prostate cancer

10.1200/jco.22.02661 · 2023 · External reference

Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel

10.1200/jco.18.01279 · 2019 · External reference

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy

10.1093/jnci/djt280 · 2013 · External reference

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer

10.1200/jco.2013.52.3696 · 2014 · External reference

Prognostic index model for progression-free survival in chemotherapy-naive metastatic castration-resistant prostate cancer treated with abiraterone acetate plus prednisone

2017 · External reference

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

10.1016/j.ebiom.2020.102728 · 2020 · External reference

Plasma cell–free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer

10.1200/po.20.00424 · 2021 · External reference

Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer

10.1016/j.eururo.2014.07.035 · 2015 · External reference

Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients

10.1038/s41391-018-0043-z · 2018 · External reference

Plasma copy number alteration-based prognostic and predictive multi-gene risk score in metastatic castration-resistant prostate cancer

10.3390/cancers14194714 · 2022 · External reference

Plasma AR and abiraterone-resistant prostate cancer

10.1126/scitranslmed.aac9511 · 2015 · External reference

Multi-gene risk score for prediction of clinical outcomes in treatment-naive metastatic castrate-resistant prostate cancer

10.1093/jncics/pkaf025 · 2025 · External reference

Pathogenic genomic alterations in circulating tumor DNA predict overall survival in men with metastatic castrate-resistant prostate cancer

2025 · External reference

Liquid biopsy testing in urological cancers: focus on urine

10.1016/j.urolonc.2025.07.034 · 2025 · External reference

Blood and urine-based biomarkers in prostate cancer: current advances, clinical applications, and future directions

10.1016/j.jlb.2025.100305 · 2025 · External reference

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

10.1038/s41591-018-0016-8 · 2018 · External reference

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes

10.1200/jco.2011.40.7379 · 2012 · External reference

Prognostic and predictive biomarker developments in multiple myeloma

10.1186/s13045-021-01162-7 · 2021 · External reference

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score

10.1182/blood.2024027540 · 2025 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Survival with olaparib in metastatic castration-resistant prostate cancer

10.1056/nejmoa2022485 · 2020 · External reference

DNA-repair defects and olaparib in metastatic prostate cancer

10.1056/nejmoa1506859 · 2015 · External reference

PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): a systematic review and meta-analysis

10.1002/bco2.455 · 2025 · External reference

Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer

10.1093/jncics/pkag042 · 2026 · External reference

Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer

10.1056/nejmoa1904819 · 2019 · External reference

Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer

10.1056/nejmoa1804710 · 2018 · External reference

Multigene copy number alteration risk score biomarker-based enrichment study designs in metastatic castrate-resistant prostate cancer

2024 · External reference

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone

10.1093/annonc/mdx689 · 2018 · External reference

Molecular profile changes in patients with castrate-resistant prostate cancer Pre- and post-Abiraterone/Prednisone treatment

10.1158/1541-7786.mcr-22-0099 · 2022 · External reference

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

10.1038/s41467-024-45475-w · 2024 · External reference

Nonparametric estimation of lifetime and disease onset distributions from incomplete observations

10.2307/2529872 · 1982 · External reference

Evaluating the yield of medical tests

10.1001/jama.1982.03320430047030 · 1982 · External reference

Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology

2013 · External reference

Integrative clinical genomics of advanced prostate cancer

10.1016/j.cell.2015.05.001 · 2015 · External reference

First-line camizestrant for emerging ESR1-Mutated advanced breast cancer

10.1056/nejmoa2502929 · 2025 · External reference

Olaparib for metastatic castration-resistant prostate cancer

10.1056/nejmoa1911440 · 2020 · External reference

Rucaparib or physician's choice in metastatic prostate cancer

10.1056/nejmoa2214676 · 2023 · External reference

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

10.1016/j.annonc.2023.06.009 · 2023 · External reference

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

10.1016/j.annonc.2022.05.519 · 2022 · External reference

Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study

10.1200/jco.18.01731 · 2019 · External reference

Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial

10.1016/j.eururo.2024.12.015 · 2025 · External reference

Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis

10.1007/s10549-022-06580-w · 2022 · External reference

Combined Tumor suppressor defects characterize clinically defined aggressive variant prostate cancers

10.1158/1078-0432.ccr-15-1259 · 2016 · External reference